<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        14-883-17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LASIX INFUSION SOLN 250 MG.
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FUROSEMIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Ampoule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        18
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        91.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SANOFI WINTHROP INDUSTRIE" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SANOFI WINTHROP INDUSTRIE
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2218]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Sanofi Arabia Trading Co. Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            sanofi-aventis
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C03CA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
            <div class="p-20 text-center font-20">
                <div class="p-10 bg-red"><i class="fa fa-times-circle"></i>&nbsp;&#x644;&#x645; &#x64A;&#x62A;&#x645; &#x625;&#x62F;&#x62E;&#x627;&#x644; &#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A;  &#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x644;&#x647;&#x630;&#x627; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621; &#x62D;&#x62A;&#x649; &#x627;&#x644;&#x622;&#x646;</div>
            </div>
    </div>
    <div id="A-div" class="box-data">
            <div class="p-20 text-center font-20">
                <span class="p-10 bg-red"><i class="fa fa-times-circle"></i>&nbsp;&#x644;&#x645; &#x64A;&#x62A;&#x645; &#x625;&#x62F;&#x62E;&#x627;&#x644; &#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A;  &#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x644;&#x647;&#x630;&#x627; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621; &#x62D;&#x62A;&#x649; &#x627;&#x644;&#x622;&#x646;</span>
            </div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lasix® 250 mg solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lasix 250 mg solution for infusion
Each ampoule with 25 ml solution for
infusion contains 266.6 mg furosemide
sodium (equivalent to 250 mg
furosemide).
Excipient with known effect:
Contains sodium (see section 4.4).
For a full list of excipients, see section
6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection / solution for
infusion
Clear, colourless solution
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lasix 20 mg/40 mg solution for injection<br />Lasix 20 mg or 40 mg solution for<br />injection is indicated when adequate<br />diuresis is not achieved with oral<br />administration of furosemide or when<br />oral use is not possible:<br />- oedemas and/or ascites resulting from<br />disorders of the heart or liver<br />- oedemas due to disorders of the<br />kidneys<br />- oedemas due to burns<br />- pulmonary oedema (e.g. in acute heart<br />failure)<br />- supporting measure in cerebral<br />oedema<br />- oliguria as a result of a gestosis, if<br />necessary after correction of a volume<br />deficiency state (oedemas and/or<br />hypertension in gestoses are not an<br />indication!)<br />- hypertensive crisis (in addition to other<br />therapeutic measures)<br />Lasix 250 mg solution for infusion<br />The use of the high-dose preparation<br />Lasix 250 mg solution for infusion is<br />indicated exclusively for patients with<br />greatly reduced glomerular filtration<br />(glomerular filtration values less than 20<br />ml/min).<br />- Imminent and already existing acute<br />renal failure (to maintain fluid excretion</p><p>and to facilitate parenteral feeding,<br />provided there is still residual filtration)<br />- Chronic renal failure in the predialytic<br />stage with fluid retention and<br />hypertension<br />- Terminal renal failure: to maintain<br />residual diuresis<br />- Nephrotic syndrome in patients who<br />do not respond to an oral dose of 120<br />mg furosemide/day (treatment of the<br />underlying disorder is the primary<br />consideration here).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The dosage should be tailored to<br />individual needs, especially according to<br />the success of therapy. The lowest dose<br />at which the desired effect is obtained<br />should always be used.<br />For adults the following dosage<br />guidelines apply:<br />Lasix 20 mg/40 mg solution for injection<br />Dosage<br />Oedemas and/or ascites resulting from<br />disorders of the heart or liver:<br />Initial dose 2-4 ml<br />(equivalent to 20-40 mg furosemide) IV.<br />With oedemas that are difficult to<br />mobilise, this dose can be repeated at<br />appropriate intervals until the onset of<br />diuresis.<br />Oedemas due to disorders of the<br />kidneys:<br />Initial dose 2-4 ml<br />(equivalent to 20-40 mg furosemide) IV.<br />With oedemas that are difficult to<br />mobilise, this dose can be repeated at<br />appropriate intervals until the onset of<br />diuresis.<br />In nephrotic syndrome the dose must be<br />carefully determined because of the risk<br />of increased side effects.<br />Oedemas due to burns:<br />The daily and/or single dose may be<br />between 4 and 10 ml (equivalent to 40-<br />100 mg furosemide), in exceptional<br />cases of impaired renal function up to<br />25 ml (equivalent to 250 mg<br />furosemide). Intravascular volume<br />deficiency must be corrected before<br />using Lasix 20 mg or 40 mg solution for<br />injection.<br />Pulmonary oedema (e.g. in acute heart<br />failure):<br />Use in conjunction with other therapeutic<br />measures. Initial dose 2-4 ml<br />(equivalent to 20-40 mg furosemide) IV.<br />If an increase in diuresis is still not<br />achieved, administration can be<br />repeated after 30-60 minutes, where<br />necessary doubling the dose.<br />As a supporting measure in cerebral<br />oedema:<br />The daily and/or single dose may be<br />between 4 and 10 ml (equivalent to 40-<br />100 mg furosemide). In exceptional<br />cases of impaired renal function up to<br />25 ml (equivalent to 250 mg furosemide)<br />may be administered.<br />Oliguria due to a gestosis:<br />The expected benefits must be very<br />carefully weighed against possible risks.</p><p>Intravascular volume deficiency must be<br />corrected before using Lasix 20 mg or<br />40 mg solution for injection.<br />The dose may be between 1 and 10 ml<br />(equivalent to 10-100 mg furosemide)<br />daily.<br />Oedemas and/or hypertension in<br />gestoses are not an indication for Lasix<br />20 mg or 40 mg solution for injection.<br />Hypertensive crisis:<br />2-4 ml (equivalent to 20-40 mg<br />furosemide) in addition to other<br />therapeutic measures.<br />Use in children:<br />Infants and children under 15 years old<br />should be given Lasix by the parenteral<br />route only as an exception in threatening<br />situations. The average daily dose is<br />0.5 mg furosemide/kg body weight. By<br />way of exception, up to 1 mg<br />furosemide/kg body weight can be<br />injected intravenously.<br />Method of administration and duration of<br />use<br />Lasix 20 mg and 40 mg solution for<br />injection are usually given intravenously.<br />In exceptional cases in which neither<br />oral nor intravenous administration is<br />possible, Lasix 20 mg or 40 mg solution<br />for injection can be administered by the<br />intramuscular route, but not in acute<br />situations (e.g. not in pulmonary<br />oedema) and not in high doses.<br />With intravenous administration, Lasix<br />20 mg or 40 mg solution for injection<br />should be injected slowly. The injection<br />speed of 0.4 ml solution for injection<br />(equivalent to 4 mg furosemide) per<br />minute must not be exceeded. In<br />patients with advanced renal failure<br />(serum creatinine &gt;5 mg/dl) the injection<br />speed should not exceed 0.25 ml<br />solution for injection per minute<br />(equivalent to 2.5 mg furosemide per<br />minute). In cases where it is necessary<br />to increase the dose to 25 ml (equivalent<br />to 250 mg furosemide), this dose should<br />be administered by means of a perfusor.<br />If necessary the solution for injection can<br />be diluted with isotonic saline solution.<br />Lasix 20 mg or 40 mg solution for<br />injection must not be mixed with other<br />medicinal products in the same syringe.<br />Care must be taken to ensure that the<br />pH of the ready-to-use injection solution<br />is in the weakly alkaline to neutral range<br />(pH not below 7). Acid solutions must<br />not be used as the active substance may<br />precipitate.<br />Lasix 250 mg solution for infusion<br />Dosage<br />Acute renal failure:<br />In patients with shock, hypovolaemia<br />and hypotension must be eliminated<br />before the start of treatment by taking<br />appropriate measures. Similarly, a<br />markedly pronounced disturbance of<br />serum electrolytes and the acid-base<br />equilibrium must be corrected. If a test<br />dose of 40 mg furosemide, injected<br />slowly by the intravenous route, does not<br />bring about increased water excretion,<br />treatment with Lasix 250 mg solution for<br />infusion can be started</p><p>50-100 mg furosemide per hour may be<br />administered over the day using a<br />perfusor. The daily dose should be<br />tailored to provide adequate diuresis, but<br />the maximum dose should not exceed<br />1500 mg furosemide per day.<br />Chronic renal failure in the predialytic<br />stage with fluid retention and<br />hypertension, nephrotic syndrome:<br />As the natriuretic response depends on<br />numerous variables, e.g. the degree of<br />renal failure, sodium balance etc. and<br />cannot therefore in principle be predicted<br />precisely in individual cases, the correct<br />dose is best determined by increasing<br />the dose gradually. Because of the<br />rapid onset of action, the dose can be<br />stepped up at &frac12; to hourly intervals. The<br />recommended initial dose should be<br />0.1 mg per minute in the form of an<br />infusion. As in patients with chronic<br />renal failure the mobilisation of fluids<br />should take place slowly, the dose<br />should be selected so that the patient<br />loses about 1 kg weight (140 mmol Na+)<br />per day on average.<br />In nephrotic syndrome the dose must be<br />carefully determined because of the risk<br />of increased side effects.<br />Use in children:<br />Infants and children under 15 years old<br />should be given Lasix by the parenteral<br />route only as an exception in threatening<br />situations. The average daily dose is<br />0.5 mg furosemide/kg body weight. By<br />way of exception, up to 1 mg<br />furosemide/kg body weight may be<br />administered intravenously.<br />Method of administration and duration of<br />use<br />Lasix 250 mg solution for infusion should<br />usually be administered by means of a<br />perfusor. The infusion rate of 0.4 ml<br />Lasix 250 mg solution for infusion per<br />minute (equivalent to 4 mg furosemide<br />per minute) must not be exceeded. In<br />patients with advanced renal failure<br />(serum creatinine &gt;5 mg/dl) the infusion<br />speed should not exceed 0.25 ml Lasix<br />250 mg solution for infusion per minute<br />(equivalent to 2.5 mg furosemide per<br />minute). If necessary, the solution for<br />infusion can be diluted with isotonic<br />saline solution.<br />The solution for infusion must not be<br />infused together with other medicinal<br />products.<br />Care must be taken to ensure that the<br />pH of the ready-to-use solution for<br />infusion is in the weakly alkaline to<br />neutral range (pH not below 7). Acid<br />solutions must not be used as the active<br />substance may precipitate.<br />Lasix 20 mg/40 mg solution for injection /<br />Lasix 250 mg solution for infusion<br />The ready-to-use preparation was found<br />to be chemically and physically stable for<br />24 hours at 25 &deg;C. From the<br />microbiological standpoint, the ready-touse<br />preparation must be administered<br />immediately.</p><p>If the ready-to-use preparation is not<br />employed immediately, the user is<br />responsible for the duration and<br />conditions of storage.<br />In order to achieve optimum efficacy and<br />suppress a counter-regulatory reaction,<br />a continuous infusion of furosemide<br />should be selected in preference to the<br />repeated administration of injections.<br />Furosemide is only administered<br />intravenously if oral application is not<br />possible or is ineffective (e.g. in patients<br />with poor intestinal absorption) or a rapid<br />effect is required. Parenteral<br />administration of Lasix should be<br />replaced by oral use as soon as<br />treatment permits.<br />The duration of use depends on the<br />nature and severity of the disorder.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lasix 250 mg solution for infusion
Lasix 250 mg solution for infusion must
not be used in:
- normal renal function or impaired renal
function with glomerular filtration
values greater than 20 ml/min,
because in these cases there is a risk
of a too pronounced water and
electrolyte loss
- hypersensitivity to furosemide,
sulfonamides (possible cross allergy
with furosemide) or any of the
excipients listed in section 6.1
- renal failure with anuria refractory to
furosemide therapy
- hepatic coma and precomatose states
associated with hepatic
encephalopathy
- severe hypokalaemia
- severe hyponatraemia
- hypovolaemia or dehydration
- nursing mothers.
Lasix 250 mg solution for infusion must
not be used for bolus injection. It must
be infused while monitoring the infusion
volume and rate to reduce the risk of
accidental overdosage.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Particularly careful monitoring is<br />necessary in:<br />- patients with hypotension</p><p>- patients with manifest or latent<br />diabetes mellitus (regular monitoring<br />of the blood sugar level)<br />- patients with gout (regular monitoring<br />of the uric acid in the serum)<br />- patients with impairment of micturition<br />(e.g. in prostatic hypertrophy,<br />hydronephrosis, ureter stenosis)<br />- patients with hypoproteinaemia, e.g. in<br />nephrotic syndrome (careful<br />adjustment of the dose)<br />- patients with hepatorenal syndrome<br />(rapidly progressing renal insufficiency<br />combined with severe hepatic disease,<br />e.g. liver cirrhosis)<br />- patients who are particularly at risk<br />from an unwanted severe fall in blood<br />pressure, e.g. those with<br />cerebrovascular circulatory disorders<br />or coronary heart disease<br />- premature infants (risk of developing<br />nephrocalcinosis/nephrolithiasis;<br />monitoring of renal function,<br />nephrosonography).<br />In premature infants with respiratory<br />distress syndrome, diuretic treatment<br />with furosemide in the first weeks of life<br />can increase the risk of persistent ductus<br />arteriosus.<br />In patients with micturition disorders<br />(e.g. in patients with prostatic<br />hyperplasia) furosemide may only be<br />used if provision has been made for a<br />free flow of urine, because a sudden<br />flood of urine can lead to urinary<br />retention with overextension of the<br />bladder.<br />Furosemide leads to increased excretion<br />of sodium and chloride and,<br />consequently, of water. Excretion of<br />other electrolytes (particularly<br />potassium, calcium and magnesium) is<br />also increased. As disturbances in the<br />fluid and electrolyte imbalance are<br />frequently observed during therapy with<br />Lasix as a result of increased electrolyte<br />excretion, regular monitoring of serum<br />electrolytes is indicated.<br />Particularly during long-term therapy<br />with Lasix the serum electrolytes<br />(especially potassium, sodium, calcium),<br />bicarbonate, creatinine, urea and uric<br />acid as well as the blood sugar should<br />be regularly monitored.<br />Particularly close supervision is<br />necessary for patients with a high risk of<br />developing electrolyte disorders or in the<br />case of severe fluid depletion (e.g. as a<br />result of vomiting, diarrhoea or intensive<br />sweating). Hypovolaemia or dehydration<br />as well as pronounced electrolyte<br />disturbances or impairment of the acidbase<br />balance must be corrected. This<br />may necessitate the temporary<br />discontinuation of treatment with<br />furosemide.<br />The possible development of electrolyte<br />disturbances is influenced by underlying<br />diseases (e.g. liver cirrhosis, heart<br />failure), co-medication (see section 4.5)<br />and diet.</p><p>The weight loss caused by increased<br />urine excretion should not exceed<br />1 kg/day irrespective of the extent of<br />urine excretion.<br />In nephrotic syndrome the dose must be<br />carefully determined because of the risk<br />of increased undesirable effects.<br />Concomitant use with risperidone<br />In risperidone placebo-controlled trials in<br />elderly patients with dementia, a higher<br />incidence of mortality was observed in<br />patients treated with furosemide plus<br />risperidone (7.3%; mean age 89 years,<br />range 75-97 years) when compared to<br />patients treated with risperidone alone<br />(3.1%; mean age 84 years, range 70-96<br />years) or furosemide alone (4.1%; mean<br />age 80 years, range 67-90 years).<br />Concomitant use of risperidone with<br />other diuretics (mainly thiazide diuretics<br />used in low dose) was not associated<br />with similar findings.<br />No pathophysiological mechanism has<br />been identified to explain this finding,<br />and no consistent pattern for cause of<br />death observed. Nevertheless, caution<br />should be exercised and the risks and<br />benefits of this combination or cotreatment<br />with other potent diuretics<br />should be considered prior to the<br />decision to use. There was no increased<br />incidence of mortality among patients<br />taking other diuretics as concomitant<br />treatment with risperidone. Irrespective<br />of treatment, dehydration was an overall<br />risk factor for mortality and should<br />therefore be avoided in elderly patients<br />with dementia (see section 4.3).<br />The use of Lasix can produce positive<br />results in doping tests. In addition, the<br />use of Lasix as a doping agent can<br />endanger health.<br />Note on specific excipients<br />Lasix 20 mg or 40 mg solution for<br />injection and Lasix 250 mg solution for<br />infusion contain sodium, but less than<br />1 mmol (23 mg) sodium per ampoule.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The simultaneous use of furosemide and<br />glucocorticoids, carbenoxolone or<br />laxatives can lead to increased<br />potassium depletion with the risk of<br />hypokalaemia developing. In this<br />respect, large amounts of liquorice act<br />like carbenoxolone.<br />Non-steroidal anti-inflammatory drugs<br />(e.g. indomethacin and acetylsalicylic<br />acid) can attenuate the effect of<br />furosemide. In patients who develop<br />hypovolaemia during furosemide therapy<br />or in dehydration, the simultaneous<br />administration of nonsteroidal antiinflammatory<br />agents can trigger acute<br />renal failure.<br />Probenecid, methotrexate and other<br />medicinal products which, like<br />furosemide, are secreted in considerable<br />amounts in the tubules of the kidneys<br />can attenuate the effect of furosemide.<br />An attenuation of the effect of<br />furosemide has been described when<br />phenytoin is administered concomitantly.</p><p>If furosemide is administered at the<br />same time as cardiac glycosides, it<br />should be borne in mind that in<br />hypokalaemia and/or hypomagnesaemia<br />developing during furosemide therapy,<br />the sensitivity of the myocardium to<br />cardiac glycosides is increased. There<br />is a greater risk of ventricular<br />arrhythmias (including torsades de<br />pointes) if furosemide and medicinal<br />products that can cause a syndrome of<br />the prolonged QT interval (e.g.<br />terfenadine, some class I and III<br />antiarrhythmic agents) are used<br />concomitantly in the presence of<br />electrolyte disturbances.<br />The toxicity of salicylates in high doses<br />can be potentiated if these medicinal<br />products are used at the same time as<br />furosemide.<br />Furosemide can potentiate the harmful<br />effects of nephrotoxic medicinal products<br />(e.g. antibiotics such as<br />aminoglycosides, cephalosporins,<br />polymyxins).<br />There may be a deterioration in renal<br />function in patients who are treated<br />concomitantly with furosemide and high<br />doses of certain cephalosporins.<br />The ototoxicity of aminoglycosides (e.g.<br />kanamycin, gentamicin, tobramycin) and<br />other ototoxic medicinal products can be<br />increased by the simultaneous<br />administration of furosemide. Any<br />hearing disorders that occur may be<br />irreversible. The simultaneous use of<br />the above mentioned medicinal products<br />should therefore be avoided.<br />If cisplatin and furosemide are<br />administered simultaneously, there is a<br />possibility that hearing damage may<br />occur. If, during cisplatin treatment,<br />forced diuresis with furosemide is<br />attempted, furosemide may only be used<br />in a low dose (e.g. 40 mg with normal<br />renal function) and when there is a<br />positive fluid balance. If not, potentiation<br />of the nephrotoxicity of cisplatin may<br />result.<br />The concomitant administration of<br />furosemide and lithium leads, via<br />reduced lithium excretion, to an increase<br />in the cardio- and neurotoxic effect of the<br />lithium. It is therefore advisable to<br />monitor carefully the plasma lithium level<br />in patients who receive this combination.<br />If other antihypertensive agents,<br />diuretics or medicinal products with<br />blood-pressure-lowering potential are<br />used at the same time as furosemide, a<br />marked fall in blood pressure is to be<br />expected. Severe falls in blood pressure<br />or even shock and a deterioration in<br />renal function (in isolated cases acute<br />renal failure) have been observed,<br />particularly when an ACE inhibitor or<br />angiotensin-II-receptor antagonist has<br />been administered for the first time or for<br />the first time in a relatively high dose. If<br />possible, the furosemide therapy should<br />therefore be temporarily discontinued, or<br />at least the dose should be reduced for<br />three days before treatment with an ACE<br />inhibitor or angiotensin-II-receptor<br />antagonist is started or its dose<br />increased.</p><p>Furosemide can reduce the renal<br />elimination of probenecid, methotrexate<br />and other medicinal products which, like<br />furosemide, are secreted in considerable<br />amounts in the tubules of the kidneys.<br />In high-dose treatment (especially with<br />both furosemide and the other medicinal<br />product), this can lead to raised serum<br />levels and a greater risk of undesirable<br />effects due to furosemide or the<br />concomitant medication. The effect of theophylline or curare-type<br />muscle relaxants may be increased by<br />furosemide.<br />The effect of antidiabetic agents or<br />hypertensive sympathomimetics (e.g.<br />epinephrine, norepinephrine) may be<br />attenuated if furosemide is used at the<br />same time.<br />In patients treated with risperidone,<br />caution should be exercised and the<br />risks and benefits of the combination or<br />co-treatment with furosemide or with<br />other potent diuretics should be<br />considered prior to the decision to use.<br />(See section 4.4 regarding increased<br />mortality in elderly patients with<br />dementia concomitantly receiving<br />risperidone.)<br />Other interactions<br />The concomitant administration of<br />cyclosporin A and furosemide is<br />associated with an increased risk of<br />gouty arthritis as a result of<br />hyperuricaemia caused by furosemide<br />and impairment, by cyclosporin, of renal<br />uric acid excretion.<br />In patients who were at high risk of renal<br />damage due to X-ray contrast media and<br />were treated with furosemide, a<br />deterioration in renal function occurred<br />more frequently after a contrast<br />examination than in at-risk patients who<br />received only an intravenous supply of<br />fluid (hydration) before the contrast<br />examination.<br />After the intravenous administration of<br />furosemide within 24 hours of taking<br />chloralhydrate, a sensation of heat,<br />outbreaks of sweating, restlessness,<br />nausea, a rise in blood pressure, and<br />tachycardia may be experienced in<br />isolated cases. The simultaneous use of<br />furosemide and chloralhydrate should<br />therefore be avoided.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Furosemide should only be used in<br />pregnancy for short periods and after<br />very carefully weighing expected<br />benefits against possible risks because it<br />crosses the placenta.<br />Diuretics are not suitable for the routine<br />treatment of hypertension and oedemas<br />in pregnancy, since they impair the<br />perfusion of the placenta and therefore<br />intrauterine growth.</p><p>If however furosemide has to be given in<br />maternal heart failure or renal<br />insufficiency, electrolytes and<br />haematocrit as well as the growth of the<br />fetus must be monitored precisely.<br />Displacement of the bilirubin from the<br />albumin binding, constituting an<br />increased risk of kernicterus in<br />hyperbilirubinaemia, has been discussed<br />in relation to furosemide.<br />Furosemide crosses the placenta and<br />reaches 100% of the maternal serum<br />concentration in cord blood. No<br />deformities in humans, which could be<br />associated with exposure to furosemide,<br />have been reported to date. There is<br />however insufficient data available to<br />make a final assessment of a possible<br />damaging effect on the embryo/fetus.<br />Urine production by the fetus in utero<br />may be stimulated. In the treatment of<br />premature infants with furosemide, the<br />occurrence of urolithiasis has been<br />observed.<br />Furosemide is excreted in the breast<br />milk and inhibits lactation. Women<br />should therefore not be treated with<br />furosemide if they are breastfeeding. If<br />necessary, they should cease<br />breastfeeding (see also section 4.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Even when used correctly, this medicinal<br />product can affect reaction to such an<br />extent that the ability to drive, use<br />machines or work without a safety rail or<br />a safe foothold may be impaired. This<br />applies particularly at the start of<br />treatment, when increasing the dose or<br />switching to another preparation or when<br />taking the drug in combination with<br />alcohol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following frequency ratings have<br />been used as a basis for assessing<br />undesirable effects:<br />Very common (&ge; 1/10)<br />Common (&ge; 1/100, &lt; 1/10)<br />Uncommon (&ge; 1/1,000, &lt; 1/100)<br />Rare (&ge; 1/10,000, &lt; 1/1,000)<br />Very rare (&lt; 1/10,000)<br />Not known (cannot be estimated<br />from the available data)<br />The frequency ratings for undesirable<br />effects are based on literature data and<br />relate to studies in which a total of 1,387<br />patients were treated with various<br />dosages of furosemide in various<br />indications.<br />Blood and lymphatic system disorders:<br />Common: haemoconcentration (if<br />diuresis is excessive).<br />Uncommon: thrombocytopenia.<br />Rare: eosinophilia, leukopenia.<br />Very rare: haemolytic anaemia, aplastic<br />anaemia, agranulocytosis.<br />Signs of agranulocytosis may be fever<br />with chills, mucosal changes and sore<br />throat.&nbsp;Immune system disorders:<br />Uncommon: mucocutaneous reactions<br />(see &ldquo;Skin and subcutaneous tissue<br />disorders&rdquo;).<br />Rare: severe anaphylactic and<br />anaphylactoid reactions such as<br />anaphylactic shock (for treatment, see<br />section 4.9).<br />Initial signs of shock include skin<br />reactions, such as flushing or urticaria,<br />restlessness, headache, sweating,<br />nausea, cyanosis.<br />Metabolism and nutrition disorders (see<br />section 4.4):<br />Very common: electrolyte disturbances<br />(including symptomatic), dehydration<br />and hypovolaemia (especially in elderly<br />patients), elevated blood triglycerides.<br />Common: hyponatraemia and<br />hypochloraemia (especially if sodium<br />chloride intake is restricted),<br />hypokalaemia (especially if potassium<br />intake is concurrently reduced and/or in<br />patients with increased potassium<br />losses, e.g. in vomiting or chronic<br />diarrhoea); blood cholesterol increased,<br />blood uric acid increased and gout flare.<br />Uncommon: glucose tolerance<br />decreased and hyperglycaemia. In<br />patients with manifest diabetes, this can<br />lead to a worsening of the metabolic<br />status. Latent diabetes may become<br />manifest (see section 4.4).<br />Not known: hypocalcaemia,<br />hypomagnesaemia, metabolic alkalosis,<br />Pseudo-Bartter syndrome in the context<br />of misuse and/or long-term use of<br />furosemide.<br />Commonly observed symptoms of<br />hyponatraemia are apathy, calf cramps,<br />anorexia, asthenia, drowsiness, vomiting<br />and confusion.<br />Hypokalaemia can manifest as<br />neuromuscular (muscle weakness,<br />paraesthesia, paresis), intestinal<br />(vomiting, constipation, meteorism),<br />renal (polyuria, polydipsia) and cardiac<br />symptoms (impulse formation and<br />conduction disturbances). Severe<br />potassium losses can lead to paralytic<br />ileus or impaired consciousness and<br />even coma.<br />Hypocalcaemia can induce tetany in rare<br />cases.<br />As a result of hypomagnesaemia, tetany<br />or occurrence of cardiac arrhythmias has<br />been observed in rare cases.<br />Nervous system disorders:<br />Common: hepatic encephalopathy in<br />patients with hepatic insufficiency (see<br />section 4.3).<br />Rare: paraesthesias.<br />Ear and labyrinth disorders:<br />Uncommon: hearing disorders, mostly<br />reversible, especially in patients with<br />renal insufficiency or hypoproteinaemia<br />(e.g. in cases of nephrotic syndrome)<br />and/or when intravenous injections are<br />too rapid. Cases of deafness,<br />sometimes irreversible have been</p><p>reported after oral or IV administration of<br />furosemide.<br />Rare: tinnitus.<br />Vascular disorders:<br />Very common (with intravenous<br />infusions): hypotension including<br />orthostatic syndrome (see section 4.4).<br />Rare: vasculitis.<br />Not known: thrombosis (especially in<br />elderly patients).<br />If diuresis is excessive, circulatory<br />complaints (including circulatory<br />collapse) can occur, especially in elderly<br />patients and children, which mainly<br />manifest as headache, dizziness, visual<br />disturbances, dry mouth and thirst,<br />hypotension and orthostatic<br />dysregulation.<br />Gastrointestinal disorders:<br />Uncommon: nausea.<br />Rare: vomiting, diarrhoea.<br />Very rare: acute pancreatitis.<br />Hepatobiliary disorders:<br />Very rare: intrahepatic cholestasis,<br />transaminases increased.<br />Skin and subcutaneous tissue disorders:<br />Uncommon: pruritus, urticaria, rashes,<br />bullous dermatitis, erythema multiforme,<br />pemphigoid, exfoliative dermatitis,<br />purpura, photosensitivity.<br />Not known: Stevens-Johnson syndrome,<br />toxic epidermal necrolysis, acute<br />generalised exanthematous pustulosis<br />(AGEP), drug rash with eosinophilia and<br />systemic symptoms (DRESS).<br />Renal and urinary disorders:<br />Very common: blood creatinine<br />increased.<br />Common: urine volume increased.<br />Rare: tubulointerstitial nephritis.<br />Not known: urine sodium increased,<br />urine chloride increased, blood urea<br />increased, symptoms of urinary<br />obstruction (e.g. in patients with prostatic<br />hypertrophy, hydronephrosis, ureteric<br />stenosis) and even urinary retention with<br />secondary complications (see section<br />4.4), nephrocalcinosis and/or<br />nephrolithiasis in preterm infants (see<br />see section 4.4), renal failure (see<br />section 4.5).<br />Congenital, familial and genetic<br />disorders:<br />Not known: increased risk of patent<br />ductus arteriosus when preterm infants<br />are treated with furosemide in the first<br />weeks of life.<br />General disorders and administration<br />site conditions:<br />Rare: fever.<br />Not known: after intramuscular injection,<br />local reactions such as pain.<br />Reporting of suspected adverse<br />reactions<br />Reporting suspected adverse reactions<br />after authorisation of the medicinal<br />product is important. It allows continued</p><p>monitoring of the benefit/risk balance of<br />the medicinal product. Healthcare<br />professionals are asked to report any<br />suspected adverse reactions via<br />Bundesinstitut f&uuml;r Arzneimittel und<br />Medizinprodukte<br />Abt. Pharmakovigilanz<br />Kurt-Georg-Kiesinger-Allee 3<br />D-53175 Bonn<br />Website: www.bfarm.de</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>a) Symptoms of overdose<br />The clinical picture in acute or chronic<br />overdose depends on the extent of water<br />and electrolyte loss. Overdosage can<br />lead to hypotension, orthostatic<br />dysregulation, electrolyte disturbances<br />(hypokalaemia, hyponatraemia,<br />hypochloraemia) or alkalosis. In more<br />severe fluid depletion, pronounced<br />hypovolaemia, dehydration, circulatory<br />collapse and haemoconcentration with a<br />tendency to thrombosis may occur. In<br />rapid water and electrolyte losses,<br />delirious states may be observed. In<br />rare cases, anaphylactic shock<br />(symptoms: sweating, nausea, cyanosis,<br />severe fall in blood pressure, clouding of<br />consciousness or even coma) may be<br />encountered.<br />b) Therapeutic measures in overdose<br />In overdose or signs of hypovolaemia<br />(hypotension, orthostatic dysregulation)<br />treatment with Lasix must be<br />discontinued immediately.<br />In addition to monitoring the vital signs,<br />repeated checks on the water and<br />electrolyte balance, the acid-base<br />equilibrium, the blood sugar and the<br />nitrogen-containing constituents of the<br />urine must be carried out and any<br />deviations corrected if necessary.<br />In patients with impaired micturition (e.g.<br />those with prostatic hyperplasia)<br />provision must be made for a free flow of<br />urine, because a sudden flood of urine<br />can lead to urinary retention with<br />overextension of the bladder.<br />Treatment for hypovolaemia:<br />volume replacement<br />Treatment for hypokalaemia:<br />potassium replacement<br />Treatment for circulatory collapse:<br />supine position with legs raised, if<br />necessary shock therapy<br />Emergency measures in the event of<br />anaphylactic shock:<br />At the first signs (e.g. skin reactions<br />such as urticaria or flushing,<br />restlessness, headache, outbreaks of<br />sweating, nausea, cyanosis):<br />- stop the injection/infusion, maintain<br />venous access.<br />- as well as the usual emergency<br />measures, place the patient in a<br />supine position with the legs raised,<br />keep the airways clear and give<br />oxygen.<br />- if necessary, implement other<br />intensive care emergency measures</p><p>(including the administration of<br />adrenaline (epinephrine), volume<br />replacement fluids, glucocorticoids).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: highceiling<br />diuretic<br />ATC Code: C03CA01</p><p>Furosemide is a potent, short- and fastacting<br />loop diuretic. By blocking the<br />Na+/2Cl-/K+ ion carrier, it inhibits the<br />reabsorption of these ions in the<br />ascending part of the loop of Henle.<br />Fractional sodium excretion can<br />constitute up to 35% of the sodium that<br />has undergone glomerular filtration. As<br />a result of the raised sodium excretion,<br />there is increased urine excretion and a<br />rise in K+ secretion in the distal tubules<br />as a secondary phenomenon due to<br />osmotically bound water. Also raised is<br />the excretion of Ca2+ and Mg2+ ions. In<br />addition to the depletion of the above<br />mentioned electrolytes, reduced<br />excretion of uric acid and impairment of<br />the acid-base balance towards metabolic<br />alkalosis can result.<br />Furosemide interrupts the<br />tubuloglomerular feedback mechanism<br />in the macula densa so there is no<br />attenuation of saluretic efficacy.<br />Furosemide leads to dose-dependent<br />stimulation of the renin-angiotensinaldosterone<br />system.<br />In heart failure, furosemide immediately<br />brings about a reduction in the preload<br />on the heart by dilating the venous<br />capacitance vessels.<br />This early vascular effect appears to be<br />mediated by prostaglandins and<br />necessitates adequate renal function<br />with activation of the renin-angiotensinaldosterone<br />system and intact<br />prostaglandin synthesis.<br />Furosemide lowers the blood pressure<br />as a result of increased sodium chloride<br />excretion and a reduced response of the<br />smooth vascular musculature to<br />vasoconstrictor stimuli, and also<br />because of a decrease in blood volume.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>After intravenous administration of<br />furosemide an onset of action can be<br />expected within 2-15 minutes.<br />Plasma protein binding of furosemide is<br />about 95%; it may be reduced in renal<br />insufficiency by up to 10%. The relative<br />volume of distribution is in the region of<br />0.2 l/kg body weight (in neonates 0.8 l/kg<br />body weight).<br />Furosemide is metabolised in the liver to<br />only a minor extent (about 10%) and is<br />mostly excreted unchanged. Two-thirds<br />of it is eliminated via the kidneys and<br />one-third in the bile and faeces. In<br />normal renal function the elimination<br />half-life is about 1 hour; it may be<br />extended to up to 24 hours in terminal<br />renal failure.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The acute oral toxicity was low in all the<br />species tested. Chronic toxicity studies<br />in rats and dogs gave rise to changes in<br />the kidneys (including fibrosis and<br />calcification of the kidneys).<br />In-vitro and in-vivo tests to investigate<br />the genetic toxicology of furosemide<br />gave no indication that might be of<br />clinical relevance relating to a genotoxic<br />potential.Long-term studies in rats and mice<br />showed no evidence of a carcinogenic<br />potential.<br />In reproductive toxicology studies,<br />following the administration of high<br />doses, a reduced number of<br />differentiated glomeruli, skeletal<br />anomalies in the scapula, humerus and<br />ribs (due to hypokalaemia) were<br />observed in rat foetuses, as well as<br />hydronephrosis in mouse and rabbit<br />foetuses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lasix 250 mg solution for infusion<br />Sodium hydroxide, mannitol (Ph.Eur.),<br />water for injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Injection solutions/infusion solutions<br />which have an acid or weakly acid<br />reaction and a pronounced buffering<br />capacity in the acid range must not be<br />mixed with Lasix solution for injection or<br />infusion. With these mixtures, the pH is<br />shifted into the acid range and the only<br />slightly water-soluble furosemide<br />precipitates out as a crystalline deposit.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lasix 250 mg solution for infusion
18 months.
The ready-to-use preparation was found
to be physically and chemically stable for
24 hours at 25 °C.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep the ampoules in the outer carton in<br />order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lasix 250 mg solution for infusion<br />Pack containing<br />4 ampoules of 25 ml each<br />6 ampules of 25 ml each<br />Hospital pack containing<br />20 (4x5) ampoules of 25 ml each<br />24 (4x6) ampoules of 25 ml each</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sanofi-Aventis Deutschland GmbH
D-65926 Frankfurt am Main, Germany
Postal address:
Postfach 80 08 60
D-65908 Frankfurt am Main, Germany
Telephone: + 49 (0)1 80 2 22 20 10*
Fax: + 49 (0)1 80 2 22 20 11*
E-mail: medinfo.de@sanofi.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October 2013
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>